Document is current
Any future updates will be listed below
-
Authors
Dreger, Peter
Holtick, Udo
Subklewe, Marion
von Tresckow, Bastian https://orcid.org/0000-0003-1410-4487
Ayuk, Francis
Wagner, Eva
Wulf, Gerald
Marks, Reinhardt
Penack, Olaf https://orcid.org/0000-0003-4876-802X
Schnetzke, Ulf
Koenecke, Christian https://orcid.org/0000-0001-7025-1735
von Bonin, Malte https://orcid.org/0000-0002-3828-0031
Stelljes, Matthias
Glass, Bertram
Baldus, Claudia D. https://orcid.org/0000-0002-0748-834X
Vucinic, Vladan https://orcid.org/0000-0002-8398-285X
Mougiakakos, Dimitrios
Topp, Max
Schroers, Roland https://orcid.org/0000-0003-2744-5491
Wolff, Daniel
Thomas, Simone
Kröger, Nicolaus
Bethge, Wolfgang A. https://orcid.org/0000-0001-6052-2618
,
,
- License Information
-
More Information
Article History
Received: 10 September 2022
Revised: 25 October 2022
Accepted: 27 October 2022
First Online: 22 November 2022
Competing interests
: PD consultancy for AbbVie, AstraZeneca, bluebird bio, Gilead, Janssen, Miltenyi, Novartis, Riemser, Roche; speakers bureau for AbbVie, AstraZeneca, Gilead, Novartis, Riemser, Roche; research support from Riemser; UH honoraria from Novartis, Gilead, BMS, Miltenyi, Roche; MS research support Amgen, BMS, Gilead, Miltenyi, MorphoSys, Novartis, Roche, Seagen, Advisory Board Amgen, BMS, Gilead, Janssen, Novartis, Pfizer, Seagen, Speaker’s Bureau Amgen, BMS, Gilead, Novartis, Pfizer, Takeda; BvT advisor or consultant for BMS/Celgene, Incyte, Miltenyi, Novartis, Pentixafarm, Amgen, Pfizer, Takeda, MSD, Gilead Kite, honoraria from AstraZeneca, Novartis, Roche, Takeda, and MSD, research funding from Novartis, MSD, Takeda, travel support from AbbVie, AstraZeneca, Kite-Gilead, MSD, Takeda, Novartis; FA honoraria from Novartis, Gilead, BMS, Janssen, Takeda, Therakos/Mallinckrodt, research funding from Therakos/Mallinckrodt; GW honoraria Gilead, Novartis, Takeda, Clinigen, Amgen; OP honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer and Therakos, research support from Gilead, Incyte, Jazz, Neovii Biotech and Takeda, advisory boards of Jazz, Gilead, MSD, Omeros, Priothera, Shionogi and SOBI; US advisory board Novartis; CK Advisory boards: Abbvie, Amgen, BMS, EusaPharm, GSK, Janssen, Kite/Gilead, Medigene, Novartis, Roche, Sanofi, Takeda, Pfizer, Incyte; MvB honoraria and travel funds Gilead, Novartis, Janssen, Takeda, Daiichi Sankyō; MSt honoraria Kite/Gilead, Jazz, MSD, Novartis, Pfizer, BMS/Celgene; CDB received honoraria and travel funds from BMS, Amgen, Novartis, Jazz, Gilead, Janssen; VV honoraria and travel funds for Gilead, honoraria and consultancies for Novartis, Gilead, BMS/Celgene; DM consultancies for AbbVie, Roche, BMS, Hexal, Novartis, MSD, Celgene, Janssen-Cilag, Pfizer, Astra-Zeneca, and Jazz Pharma; DW honoraria from Behring, BMS, Gilead, Novartis, Takeda; research support from Novartis; ST honoraria and travel funds Abbvie, BMS/Celgene, EUSA Pharma, Janssen, Gilead, Medigene, Novartis, Pfizer; Research funding BMS/Celgene, Gilead; NK honoraria Kite/Gilead, Jazz, MSD, Neovii Biotech, Novartis, Riemser, Pfizer, BMS Research support from Neovii, Riemser, Novartis, BMS; WB honoraria and travel funds Gilead, Novartis, Miltenyi and Janssen, Research grants Miltenyi. BG, RM, RS, MT and EW declare no competing interests.
